Q4 2021 Orexo AB Earnings Call Transcript
Hello, and welcome to the Orexo Q4 interim report. (Operator Instructions) Today, I am pleased to present CEO, Nikolaj Sørensen; CFO, Joseph DeFeo; and Robert Ronn, Head of R&D. Please go ahead.
¸ - ()-&
Thank you very much, and welcome to this fourth quarter interim report presentation. It's clearly been an eventful day on the stock exchange, and I can understand there is some anxiety around Orexo. And having listened to some investors and analysts, I understand some of the concern is around the profitability and our Digital Therapies. So I would put a little extra emphasis on these 2 areas and hopefully create some calm about the situation for the company.
So today, and I'm moving to Page #2. We will go through some highlights for the quarter. I will talk about some of the business updates in U.S. Pharma, a little on the pipeline, but I'm joined by Robert Ronn, who will talk a little bit about our new technology platform amorphOX, our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |